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Results: SBRT treatment: maximum small bowel and 
duodenum dose-volume constraints were exceeded in 5/30 
(16.7%) and 2/30 (6.7%), respectively. Dose to OARs was: 
small bowel: Dmax 31.5-40.5 Gy, V30 0.2-13.4 cc; duodenum: 
Dmax 35.7-36.6 Gy, V30 2.1-3.7 cc. 
SBRS treatment: maximum small bowel and duodenum dose-
volume constraints were exceeded in 2/21 patients (9.5%) 
and 1/21 patient (4.7%), respectively. Dose to OARs was: 
small bowel: Dmax 15.6-16.3 Gy, V12 1.7-8.5 cc; duodenum 
Dmax 16.0 Gy, V12 0.1 cc. 
With a median follow up of 24 months after SBRT and 18 
months after SBRS, no early or late severe toxicity was 
observed in patients in whom constraints were not respected. 
 
Conclusion: Patients irradiated on small bowel and 
duodenum did not develop severe toxicity although the 
administered doses were above constrains proposed in 
literature. A prolonged follow-up and a larger population are 
needed to confirm the safety of dose-volume constraints 
other than those reported in literature about SBRT and SBRS 
on abdominal area. 
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Purpose or Objective: To define the maximum tolerated 
dose (MTD) of extra-cranial stereotactic treatment (SBRT) in 
previously irradiated patients. 
 
Material and Methods: In a dose escalation (Phase I) study, 
previously irradiated patients were enrolled in two different 
arms depending on treatment site and previous dose: 1) 
retreatment with previous dose > 60 Gy or retreatment of 
pancreatic and pelvic tumors, 2) retreatment with previous 
dose < 60 Gy. SBRT was delivered in 5 fractions with static 3D 
technique (4 non-coplanar beams) or dynamic arc (VMAT). 
The dose was prescribed at the isocenter. The Planning 
Target Volume (PTV) was defined as the GTV + 5-15 mm 
margin. According to the study arm, the first cohort of 6 
patients received a dose of 20 or 25 Gy, and subsequent 
cohorts of patients received doses up to 40 Gy. The dose 
limiting toxicity (DLT) was defined as any acute and late 
toxicity Grade ≥ 3. The MTD was defined a s the dose level 
with 2/6 or 4/12 DLT. 
 
Results: From September 2004 to December 2014, 51 
patients (M/F: 27/24; median age 65, range 44-87), 
previously irradiated with doses of 30 to 87 Gy (median dose 
50 Gy) were enrolled, after 4-228 months from the first 
treatment (median 11 months). Sixty-six lesions were treated 
(23 primary lesions or relapses, 43 lymphadenopathies) 
mainly from gynecological tumors (30%), followed by 
gastrointestinal tumors (26%) and prostatic tumors (17%). 
Nineteen of the 66 lesions were in the neck or chest, 22 in 
the abdomen and 25 in the pelvis. With a median follow-up of 
19 months (3-104), an overall response rate of 81% (Complete 
Response: 55%, Partial Response: 26%), with only 3% of 
disease progression was recorded. At 40 Gy dose-level, only 1 
patient showed DLT (cutaneous fistula in the sacral region). 
Two-year local control was 75% and 2-year metastasis-free 
survival was 30%. 
 
Conclusion: SBRT treatment in 5 fractions up to a dose of 40 
Gy is well tolerated in previously irradiated patients. This 
dose escalation protocol is still ongoing (Table 1). 
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Purpose or Objective: To define the maximum tolerated 
dose (MTD) of stereotactic extracranial radiosurgery 
performed in a single session (SBRS) in different clinical 
settings. 
 
Material and Methods: Based on a Dose Escalation study 
(Phase I), oligometastatic patients were enrolled in 4 
different arms depending on site and treatment purpose: 1) 
liver metastases, 2) lung metastases, 3) lymph node 
metastases or liver or lung metastases with a prolonged local 
control purpose, 4) bone metastases (non-vertebral). Dose 
was prescribed according to the Rosel protocol (V100 >95%, 
V90 >99% and Dmax <140% of the prescription) with dynamic 
